# HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Source: https://onco.cc/trials/nct06014190/  
OnCo record `nct06014190` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HS-20089 in ovarian cancer and endometrial cancer, run by Hansoh BioMedical R&D Company, now recruiting.

## Summary

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer is a phase 2 interventional study registered as NCT06014190 by Hansoh BioMedical R&D Company, with 460 participants planned, started 2023-12-18 and due to reach its primary completion in 2025-12-31. Interventions recorded: HS-20089. Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06014190
- Phase: 2
- Setting: A Phase 2 Study of HS-20089 for Injection in Patients With Recurrent or Metastatic Ovarian Cancer and Endometrial Cancer
- Sponsor: Hansoh BioMedical R&D Company
- Enrolled: 460

## Sources

- ClinicalTrials.gov NCT06014190: https://clinicaltrials.gov/study/NCT06014190

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [HS-20089](https://onco.cc/drugs/hs-20089/)

---
JSON: https://onco.cc/api/v1/entities/nct06014190.json